The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the ...

A large, population-based study of patients with atrial fibrillation (AF) and valvular heart disease (VHD) found that use of apixaban was associated with a lower rate of ischemic stroke or systemic ...

In the COMPASS trial of patients with stable coronary or peripheral artery disease (PAD), the combination of aspirin plus rivaroxaban, 2.5 mg twice daily, provided a larger absolute benefit on ...

Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and safety of rivaroxaban ...

August 10, 2011 (Durham, North Carolina) — A major clinical trial showing that rivaroxaban (Xarelto, Bayer/Johnson & Johnson) is noninferior to dose-adjusted warfarin for the prevention of stroke or ...

BOSTON, MA—For patients undergoing transradial coronary procedures, a short course of rivaroxaban (Xarelto; Bayer/Janssen) reduces the rate of radial artery occlusion without significantly increasing ...

In PAD patients with chronic kidney disease who’ve undergone revascularization, rivaroxaban (Xarelto; Bayer/Janssen) can safely reduce major CV and limb events, new findings from the VOYAGER PAD trial ...

Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients ...

What if you Miss a Dose of Rivaroxaban? Stopping Rivaxoraban may increase your risk of having a stroke or forming blood clots in other parts of your body. In case of missing a dose, take the tablet ...

In 2008, rivaroxaban (Xarelto; Bayer HealthCare) became the first orally administered direct factor Xa inhibitor to be approved for clinical use in the prevention of venous thromboembolism (VTE) after ...